Neurology · Little Rock, AR
Neurology studies in Little Rock, AR
22 recruiting studies have a site in Little Rock.
22 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Little Rock, AR + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals
- Location
- Little Rock, AR + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Little Rock, AR + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Little Rock, AR + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Little Rock, AR + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Little Rock, AR + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Little Rock, AR + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Little Rock, AR + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Little Rock, AR + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Little Rock, AR + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Little Rock, AR + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Little Rock, AR + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Little Rock, AR + 111 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Little Rock, AR + 33 other US sites
- Eligibility basics
- Ages 45–75
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Little Rock, AR + 69 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Little Rock, AR + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Sangamo Therapeutics
- Location
- Little Rock, AR + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Neurona Therapeutics
- Location
- Little Rock, AR + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Impax Laboratories, LLC
- Location
- Little Rock, AR + 22 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Encore PFO Closure Device - The PerFOrm Trial
Encore Medical Inc.
- Location
- Little Rock, AR + 7 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Duke University
- Location
- Little Rock, AR + 88 other US sites
- Eligibility basics
- Ages 75+
- RecruitingHealthy volunteers
A rTMS and Virtual Reality Based Cognitive Rehabilitation Program for MCI
Central Arkansas Veterans Healthcare System
- Location
- Little Rock, AR
- Eligibility basics
- Ages 55+
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.